Mona Ashiya Sells 39,656 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 39,656 shares of the company’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12. Following the transaction, the director now owns 188,981 shares in the company, valued at approximately $10,208,753.62. This trade represents a 17.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total transaction of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34.

Disc Medicine Trading Down 1.9 %

Disc Medicine stock opened at $52.24 on Friday. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $68.73. The stock’s 50 day simple moving average is $55.26 and its two-hundred day simple moving average is $56.02. The firm has a market cap of $1.81 billion, a PE ratio of -13.13 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, equities research analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its position in shares of Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after buying an additional 503 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Disc Medicine during the 4th quarter valued at approximately $40,000. Tower Research Capital LLC TRC lifted its position in shares of Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after buying an additional 266 shares in the last quarter. Quest Partners LLC purchased a new position in shares of Disc Medicine during the 3rd quarter valued at approximately $131,000. Finally, Quantbot Technologies LP purchased a new position in shares of Disc Medicine during the 3rd quarter valued at approximately $146,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Cantor Fitzgerald upped their target price on Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday. Morgan Stanley reiterated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Wedbush reiterated an “outperform” rating and issued a $90.00 target price (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, Scotiabank upped their target price on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.